Abstract B cell maturation antigen (BCMA) is an ideal target for precise treatment due to its highly selective expression on malignant myeloma cells. This review summarizes briefly the advances in the latest research progress on biological activity of BCMA, its significance as a biomarker and immunotherapy direcited against BCMA, such as bispecific antibodies, antibody drug conjugates, chimeric antigen receptor T cell therapy against mature B cell antigens.
题目: B细胞成熟抗原（BCMA）靶向免疫治疗多发性骨髓瘤的研究进展.
摘要: B细胞成熟抗原（B cell maturation antigen，BCMA）因其在恶性骨髓瘤细胞上高度选择性表达，故是理想的精准治疗靶点。本文就BCMA的生物学活性、作为生物标志物的意义以及针对抗B细胞成熟抗原开发的免疫疗法（双特异性抗体，抗体药物偶联物，嵌合抗原受体T细胞疗法）的最新研究进展作一综述。.